<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683627</url>
  </required_header>
  <id_info>
    <org_study_id>HP-5000-US-07</org_study_id>
    <nct_id>NCT04683627</nct_id>
  </id_info>
  <brief_title>A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee</brief_title>
  <official_title>A 12-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of HP-5000 Topical System (Patch) in Subjects With Osteoarthritis Pain of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 study to&#xD;
      Evaluate the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) Pain of the&#xD;
      Knee&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, and placebo-controlled phase 3 study&#xD;
      evaluating the safety and efficacy of HP-5000 in subjects with OA pain of the knees. The&#xD;
      study will consist of up to a 28-day Screening Phase that will include a Washout Period of&#xD;
      current prescription and over the counter (OTC) analgesics; a 12-week Double-blind Treatment&#xD;
      Phase, and a 1-week safety Follow-up Phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Osteoarthritis of the Knee pain score between Baseline and Week 12. Primary efficacy endpoint</measure>
    <time_frame>12-week vs. baseline</time_frame>
    <description>Evaluate efficacy and safety of HP-5000 topical patches in subjects with OA of the knee by measuring change in Osteoarthritic pain score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Osteoarthritis Pain of the Knee</condition>
  <arm_group>
    <arm_group_label>HP-5000 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HP-5000 Topical Patch will be evaluated against placebo topical patches.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patches without diclofenac sodium will be used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac sodium active topical patch</intervention_name>
    <description>A topical patch with diclofenac sodium will be evaluated against the placebo patch for the treatment of OA pain of the knee</description>
    <arm_group_label>HP-5000 Treatment</arm_group_label>
    <other_name>HP-5000</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>A placebo patch without diclofenac sodium will be used for the placebo arm.</description>
    <arm_group_label>Placebo Treatment</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 40 to 85 years with a clinical diagnosis of OA of the target knee&#xD;
             according to the American College of Rheumatology criteria.&#xD;
&#xD;
          -  Has an X-ray of the target knee, taken no more than 1 year before Baseline, showing&#xD;
             evidence of OA.&#xD;
&#xD;
          -  Has pain of OA in the designated/target study knee.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 40.&#xD;
&#xD;
          -  Any subject who did not follow the restriction of prohibited therapies during Washout&#xD;
             period.&#xD;
&#xD;
          -  Arthritis of the target knee that is not caused by OA but caused by diseases such as&#xD;
             rheumatoid arthritis, gout, psoriasis, syphilitic arthropathy, ochronosis, metabolic&#xD;
             or other primary bone disease, or acute traumatic injury.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Noven Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>(305) 253-5099</phone>
    <email>ClinicalTrials@noven.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Noven Pharmaceuticals, Inc.</name>
      <address>
        <city>Jersey City</city>
        <state>New Jersey</state>
        <zip>07310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

